Profil Disolusi Terbanding, Penetapan Kadar, dan Kualitas Fisik Tablet Atorvastatin Inovator, Generik Bernama Dagang, dan Generik

  • Nurul Aini Pusat Biomedis dan Teknologi Dasar Kesehatan, Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan,Jakarta,Indonesia
  • Ratih Dian Saraswati Pusat Biomedis dan Teknologi Dasar Kesehatan, Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan,Jakarta,Indonesia
  • Intan Sari Oktoberia Pusat Biomedis dan Teknologi Dasar Kesehatan, Badan Penelitian dan Pengembangan Kesehatan, Kementerian Kesehatan,Jakarta,Indonesia
Keywords: Atorvastatin tablets, Dissolution profile, HPLC, Assay, Physical quality

Abstract

Atorvastatin is one of the statins which is used as the first line therapy for hyperlipidemia. The patent of atorvastatin innovator ended in 2011. Besides the innovator brand of atorvastatin, several brand and one generic atorvastatin tablet are currently marketed in Indonesia. In this research, dissolution profiles, assay and physical quality were investigated for three atorvastatin tablet samples consist of one innovator sample, two atorvastatin copy layer products (branded generic atorvastatin sample and atorvastatin generic sample). The dissolution testing were done using FDA (Food and Drug Administration) method. The result shows that the innovator and branded generic samples meet all the requirements for physical quality, meanwhile the generic sample failed to meet the disintegration test criteria. The branded generic sample has similar dissolution profile with the innovator, while the generic tablet was not similar. The assay were conducted using High Performance Liquid Chromatography (HPLC) method. The assay result of the innovator, branded generic, and generic samples respectively were 97,54%, 106,36% and 97,65% which means that all samples comply with general requirement of active pharmaceutical ingredient in tablet.

References

Brunton L, Parker K, Blumenthal D, Buxton I, editors. Terapi obat untuk hiperkolesterolemia dan dislipidemia, dalam Goodman & Gilman: Manual farmakologi dan terapi. Jakarta: Penerbit Buku Kedokteran EGC; 2010.

Van der Most PJ, Dolga AM, Nijholt IM, Luiten PGM, Eisel ULM. Statins: Mechanisms of neuroprotection. Prog Neurobiol [Internet]. 2009 [cited 2013 Oct 29];88(1):64–75. Available from: http://www.sciencedirect.com/science/article/pii/S0301008209000318

Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef a F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hyper-cholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet [Internet]. 2001 Feb 24;357(9256):577–81. Available from: http://www.ncbi. nlm.nih.gov/pubmed/11558482

Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. J Cardiovasc Pharmacol Ther. 2000;5(1):27–32.

Harper M, Kang P. The world’s ten best selling drugs [Internet]. Available from: www.forbes.com

Bartholow M. Top 200 drugs of 2010 [Internet]. Available from: www. pharmacytimes.com

Top 100 drugs for 2011 [Internet]. Available from: www.drugs.com

Badan POM RI. Peraturan Kepala Badan POM RI No. HK.03.1.23.10.11.08481 tahun 2011 tentang Kriteria dan Tata Laksana Registrasi Obat. Jakarta: Badan POM RI; 2011.

Peraturan Menteri Kesehatan Republik Indonesia No. HK.02.02/MENKES/068/

tentang Kewajiban Menggunakan Obat Generik di Fasilitas Pelayanan Kesehatan Pemerintah. Jakarta: Kementerian Kesehatan Republik Indonesia; 2010.

Yunarto N. Revitalisasi obat generik: hasil uji disolusi obat generik tidak kalah dengan obat bermerk. Media Penelit dan Pengemb Kesehat. 2010;20(4):198–202.

Popy FA, Dewan I, Parvin N, Islam SMA. Evaluation of in vitro equivalence for tablets containing the poorly water-soluble compound atorvastatin. Dissolution Technol. 2012;30–3.

Cardot J, Beyssac E, Alric M. In vitro–in vivo correlation: importance of dis-solution in IVIVC. Dissolution Technol. 2007;15–9.

Oishi TS, Nimmi I, Islam SMA. Comparative in vitro bioequivalence analysis of some generic tablets of atorvastatin, a BCS class II compound. Bangladesh Pharm J. 2011;14(1):61–6.

Allen L V, Popovich NG, Ansel HC. Ansel’s pharmaceutical dosage forms and drug delivery systems. 9th ed. Troy DB, editor. Philladelphia: Lippincott Williams & Wilkins; 2011.

The United States Pharmacopeial Convention. The United States Pharmacopeia-National Formulary. 34th ed. Maryland: The United States Pharmacopeia Convention; 2011.

Farmakope Indonesia III. Jakarta: Departemen Kesehatan RI; 1979.

Food and Drug Administration. FDA dissolution methods for drug products [Internet]. Available from: http://www.

accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_Dissolutions.cfm

Food and Drug Administration. Guidance for industry: dissolution testing of immediate release solid oral dosage forms [Internet]. 1997. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070237.pdf

Krämer J. Establishing a relationship between disintegration and dissolution [Internet]. 2009 [cited 2014 Dec 18]. Available from: https://www.aaps.org/ uploadedFiles/Content/Sections_and_Groups/Focus_Groups/KramerSA2.pdf

Brunton LL, Parker KL, Blumenthal DK, Buxton ILO, editors. Goodman & Gilman: manual farmakologi dan terapi. Jakarta: EGC; 2010.

Jones D. Fasttrack pharmaceutics: Dosage form and design. London: Pharmaceutical Press; 2008.

Augsburger L, Hoag S, editors. Pharmaceutical Dosage Forms - Tablets Volume 1 [Internet]. 3rd ed. New York: Informa Healthcare; 2008. Available from:http://www.crcnetbase.com/isbn/9781420025989

De Oliveira MA, Lacerda CD, Bonella AF. Developing methods to compare tablet formulations of atorvastatin. Brazillian J Pharm Sci [Internet]. 2012;48(4):801–10. Available from: http://www.scielo.br/pdf/bjps/v48n4/v48n4a24.pdf

Hasson K. Enhancement of atorvastatin tablet dissolution using acid medium introduction. Iraqi J Pharm Sci. 2010;19(1):82–5.

Akinleye MO, Idris O, Nwachukwu PN, Oyetunde OO. Quality of brands of atorvastatin calcium tablets marketed in Lagos, Nigeria. Int J Pharm Pharmacol. 2012;1(1):1–7.

Published
2015-08-31
How to Cite
1.
Aini N, Saraswati RD, Oktoberia IS. Profil Disolusi Terbanding, Penetapan Kadar, dan Kualitas Fisik Tablet Atorvastatin Inovator, Generik Bernama Dagang, dan Generik. jki [Internet]. 31Aug.2015 [cited 20May2022];5(2):90-7. Available from: https://ejournal2.litbang.kemkes.go.id/index.php/jki/article/view/3689
Section
Articles